Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Nov 23, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment method to help children with leukemia who need a stem cell transplant. The researchers want to see if a combination of medications, called PT/FLU+CY, can improve the chances of successful engraftment, which means that the new stem cells from cord blood can successfully grow and function in the child's body. This is particularly important for kids who are receiving stem cells from unrelated donors, using a method known as haplo-cord transplantation.
To participate in this trial, children who have been diagnosed with acute leukemia may be eligible. However, children with multi-organ dysfunction syndrome (MODS) cannot join. Those who take part in the trial will receive the new treatment and will be monitored closely by medical professionals to assess how well the treatment works and to ensure their safety. This trial is currently recruiting participants, and it aims to provide valuable information that could help improve outcomes for children battling leukemia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • children acute leukemia
- Exclusion Criteria:
- • MODS
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Xiaoqin Feng, MD
Principal Investigator
Department of Pediatrics, Nanfang Hospital, Southern Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported